Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine

International Journal of Cancer

Volumn 75, Issue 2, 1998, Pages 295-302

  Samuel, John ^a   Budzynski, Wladyslaw A ^b   Reddish, Mark A ^b   Ding, Lei ^b   Zimmermann, Gabrielle L ^a   Krantz, Mark J ^b   Koganty, R Rao ^b   Longenecker, B Michael ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Biomira Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; DIPALMITOYLPHOSPHATIDYLCHOLINE; LIPOSOME; PHOSPHORYL LIPID A; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG FORMULATION; DRUG SCREENING; FEMALE; IMMUNOGENICITY; LUNG METASTASIS; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

AMINO ACID SEQUENCE; ANIMALS; CA-15-3 ANTIGEN; CANCER VACCINES; FEMALE; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL;

EID: 0032545730     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980119)75:2<295::AID-IJC20>3.0.CO;2-B     Document Type: Article

References (28)

1. ACRES, R.B., HAREUVENI, M., BALLOUL, J.-M. and KIENY, M.-P., Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen. J. Immunother., 14, 136-143 (1993).
2. ALVING, C.R., Liposomes as carriers of antigens and adjuvants. J. Immunol. Methods., 140, 1-13 (1991).
3. APOSTOLOPOULOS, V., PIETERSZ, G.A. and MCKENZIE, I.F.C., Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine. 14, 930-938 (1996).
4. APOSTOLOPOULON, V., XING, P. and MCKENZIE., I.F.C., Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens. Cancer Res., 54, 5186-5193 (1994).
5. BAKER, P.J., HIERNAUX, J.R., FAUNTLEROY, M.B., PRESCOTT, B., CANTRELL, J.L, and RUDBACM, J.A., Inactivation of suppressor T-cell activity by nontoxic monophosphoryl lipid A. Infect. Immun., 56, 1076-1083 (1988).
6. DING, L., LALANI, E.N., REDDISM, M., KOGANTY, R., WONG, T., SAMUEL, J., YACYSHYN, M.B., MEIKLE, A., FUNG, P.Y.S., TAYLOR-PAPADIMITRIOU, J. and LONGENECKER, B.M., Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC-1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with human MUC-1 gene. Cancer Immunol. Immunother., 36, 9-17 (1993).
7. FRIES, L.F., GORDON, D.M., RICHARDS, R.L., EGAN, J.E., HOLLINGDALE, M.R., GROSS, M., SILVERMAN, C. and ALVING, C.R., Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc. nat. Acad. Sci. (Wash.), 89, 358-362 (1992).
8. GENDLER, S., TAYLOR-PAPADIMITRIOU, J., DUHIG, T., ROTHBARTH, J. and BURCWELL, J., A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J. Biol. Chem., 263, 12820-12823 (1988).
9. GENDLER, S.J., LANCASTER, C.A., TAYLOR-PAPADIMITRIOU, J., DUHIG, T., PEAT, N., BURCHELL, J., PEMBERTON, L., LALANI, E.-N. and WILSON, D., Molecular cloning and expression of the human tumor-associated polymorphic epithelial mucin PEM. Biol. Chem., 265, 15286-15293 (1990).
10. GILEWSKI, T., ADLURI, R., ZHANG, S., HOUGHTON, A., NORTON, L. and LIVINGSTON, P., Preliminary results: vaccination of breast cancer patients (PTS) lacking identifiable disease (NED) with MUC-1-keyhole limpet hemocyanin (KLH) conjugate and QS21. Proc. ASCO, 15, 555, abstract 1807 (1996).
11. GOYDOS, J.S., ELDER, E., WHITESIDE, T.L., FINN, O.J. and LOTZE, M.T., A phase I trial of a synthetic mucin peptide vaccine. J. Surg. Res., 63, 298-304 (1996).
12. GRAHAM, R.A., BURCHELL, J.M., BEVERLEY, P. and TAYLOR-PAPADIMITRIOU, J., Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int. J. Cancer, 65, 64-670 (1996).
13. GUSTAFSON, G.L. and RHODES, M.J., Effects of tumor necrosis factor and dexamethasone on the regulation of Interferon-γ induction by monophosphoryl lipid A. J. Immunother., 15, 129-133 (1994).
14. HAREUVENI,M., GAUTIER,C., KIENY, M.-P., WRESCHNER, D., CHAMBON, P. and LATHE, R., Vaccination against tumor cells expressing breast cancer epithelial tumor antigen. Proc. nat. Acad. Sci. (Wash.), 87, 9498-9502 (1990).
15. LALANI, E.N., BERDICHEVSKY, R. BOSHELL, M., SHEARER, M., WILSON, D., STAUSS, D., GENDLER, S.J. and TAYLOR-PAPADIMITRIOU, J., Expression of the gene coding for a human mucin in mouse mammary tumor cells can affect their tumorigenicity. J. biol. Chem., 266, 15420-15426 (1991).
16. LAN, M.S., BATRA, S.K., QUI, W.-N., METZGAR, R.S. and HOLLINGSWORTH, M.A., Cloning and sequencing of a human pancreatic tumor mucin cDNA. J. biol. Chem., 265, 15294 (1990).
17. LONGENECKER, B.M. and MACLEAN, G.D., Prospects for mucin epitopes in cancer vaccine. Immunologist, 1, 89-93 (1993).
18. LONGENECKER, B.M., REDDISH, M.A., KOGANTY, R.R., BUDZYNSKI, W., DING, L. and MACLEAN, G.D., Cancer vaccines which target carbohydrate. glycopeptide and peptide mucin epitopes. In: Cambridge Symposia "Discovery and Development of Tumor Vaccines." Taos New Mexico (1996).
19. PECHER, G. and FINN, O.J., Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells. Proc. nat. Acad. Sci. (Wash.), 93, 1699-1704 (1996).
20. REDDISH, M., BLACK, N., ALMEIDA, A., SURESH, M.R. and LONGENECKER, B.M., Epitope mapping of MAb B27.29 within the peptide core of the malignant breast carcinoma-associated mucin antigen coded for the human MUC1 gene. J. Tumor Marker Oncol., 7, 19-27 (1992).
21. TAYLOR-PAPADIMITRIOU, J. and GENDLER, S.J., Molecular aspects of mucins. In: J. Hilgers, and S. Zotter (eds.), Cancer reviews (Vol. 11-12), pp. 11-24. Munskgaard, Copenhagen, Denmark (1988).
22. TAYLOR-PAPADIMITRIOU, J., STEWART, L., BURCHELL, J. and BEVERLEY, P., The polymorphic epithelial mucin as a target for immunotherapy. Ann. N.Y. Acad. Sci., 690, 69 (1993).
23. ULRICH, J.T. and MYERS, K.R., Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. In: M.F. Powell and M.J. Newman (eds.), Vaccine design: the subunit and adjuvant approach pp. 495-524, Plenum, New York (1995).
24. XING, P., MICHAEL, M., APOSTOLOPOULOS, V., PRENZOSKA, J., MARSHALL, C., BISHOP, J. and MCKENZIE, I.F.C., Phase I study of synthetic MUC1 peptides in breast cancer. Int. J. Oncol., 6, 1283-1289 (1995).
25. XING, P.-X., PRENZOSKA, J., QUELCH, K. and MCKENZIE, I.F.C., Second generation anti-MUC1 peptide monoclonal antibodies. Cancer Res., 52, 2310-2317 (1992).
26. ZHANG, S., GRAEBER, L.A., HELLING, F., RAGUPATHI, G., ADLURI, S., LLOYD, K.O. and LIVINGSTON, P.O., Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. Cancer Res., 56, 3315-3319 (1996).
27. ZHOU, F. and HUANG, L., Monophosphoryl lipid A enhances specific CTL induction by a soluble protein antigen entrapped in liposomes. Vaccine, 11, 1139-1144 (1993).
28. ZIMMERMANN, G. and LONGENECKER, B.M., Influence of levels of MUC-1 expression on a tumour cell lines metastatic potential. Proc. of the 9th Int. Congress Immunol., San Francisco, p. 896, abstract 5199 (1995).